IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Atalan Capital Partners LP

Atalan Capital Partners LP trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV) by 6.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 520,000 shares of the medical research company’s stock after selling 35,000 shares during the period. IQVIA accounts for about 10.6% of Atalan Capital Partners LP’s investment portfolio, making the stock its 6th largest position. Atalan Capital Partners LP owned approximately 0.29% of IQVIA worth $123,224,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in IQV. Versant Capital Management Inc increased its position in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new position in IQVIA in the second quarter worth $27,000. Capital Performance Advisors LLP bought a new stake in IQVIA in the 3rd quarter valued at $27,000. Park Place Capital Corp bought a new position in shares of IQVIA during the 3rd quarter worth about $28,000. Finally, Itau Unibanco Holding S.A. bought a new stake in IQVIA in the second quarter valued at about $29,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.3 %

NYSE IQV opened at $200.84 on Monday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock’s 50-day moving average is $218.67 and its 200-day moving average is $226.11. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The firm has a market cap of $36.45 billion, a P/E ratio of 26.36, a P/E/G ratio of 2.07 and a beta of 1.51.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IQV. Robert W. Baird dropped their target price on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Evercore ISI lowered their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, The Goldman Sachs Group reduced their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.